First-in-Human trial tests engineered immune cells to fight rare blood cancer
NCT ID NCT07257640
Summary
This early-stage study is testing the safety and initial effectiveness of a new cell therapy called IL-5 CAR-T for adults with a rare and aggressive blood cancer called eosinophilic leukemia that has not responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a specific protein (CD125) on the cancer cells, and then infuse them back into the patient. The main goal is to see if this approach is safe and if it can help control the disease in patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of medical college of zhejiang university
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.